Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Afamelanotide

FDA-approved product (implant, subcutaneous), marketed as Scenesse.

Registered studies
23
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Afamelanotide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Erythropoietic protoporphyria

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Protectives against uv-radiation for systemic use
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA65.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli62.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis66.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

23registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Afamelanotide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Afamelanotide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Phase II Confirmatory Study in Erythropoietic Protoporphyria (EPP)

    NCT01097044 · start 2010-04

    Registered record
    Registry ID
    NCT01097044
    Conditions
    Erythropoietic Protoporphyria
    Interventions
    Afamelanotide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-04
    Completion
    2011-04
    Enrolment
    77

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErythropoietic Protoporphyria
    InterventionAfamelanotide; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Phase III Confirmatory Study in Erythropoietic Protoporphyria (EPP)

    NCT00979745 · start 2009-09

    Registered record
    Registry ID
    NCT00979745
    Conditions
    Erythropoietic Protoporphyria
    Interventions
    Afamelanotide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-09
    Completion
    2011-05
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErythropoietic Protoporphyria
    InterventionAfamelanotide; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Implant Pharmacokinetic and Pharmacodynamic Study

    NCT03634137 · start 2009-09

    Registered record
    Registry ID
    NCT03634137
    Conditions
    Healthy
    Interventions
    Afamelanotide Group 1; Afamelanotide Group 2
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-09
    Completion
    2010-03
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionAfamelanotide Group 1; Afamelanotide Group 2
    PhasePhase 1
    Registry statusCompleted

  • Phase II Solar Urticaria (SU) Pilot Study

    NCT00859534 · start 2008-12

    Registered record
    Registry ID
    NCT00859534
    Conditions
    Solar Urticaria
    Interventions
    afamelanotide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-12
    Completion
    2009-07
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolar Urticaria
    Interventionafamelanotide
    PhasePhase 2
    Registry statusCompleted

  • Afamelanotide as Adjunctive Therapy in Patients Undergoing Photodynamic Therapy (PDT) Utilising Porfimer Sodium

    NCT04425746 · start 2008-08-05

    Registered record
    Registry ID
    NCT04425746
    Conditions
    Patients Undergoing Photodynamic Therapy Using Porfimer Sodium
    Interventions
    Afamelanotide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-08-05
    Completion
    2009-05-28
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPatients Undergoing Photodynamic Therapy Using Porfimer Sodium
    InterventionAfamelanotide; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Phase II AK Study in Organ Transplant Patients

    NCT00829192 · start 2007-11

    Registered record
    Registry ID
    NCT00829192
    Conditions
    Actinic Keratoses; Carcinoma, Squamous Cell; Organ Transplant Recipients
    Interventions
    Afamelanotide (CUV1647); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2007-11
    Completion
    2012-08
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionActinic Keratoses; Carcinoma, Squamous Cell; Organ Transplant Recipients
    InterventionAfamelanotide (CUV1647); Placebo
    PhasePhase 2
    Registry statusUnknown

  • Phase III Trial of CUV1647 in Polymorphic Light Eruption (PLE)

    NCT00472901 · start 2007-05

    Registered record
    Registry ID
    NCT00472901
    Conditions
    Polymorphic Light Eruption (PLE)
    Interventions
    Afamelanotide (CUV1647)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2007-05
    Completion
    2010-09
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolymorphic Light Eruption (PLE)
    InterventionAfamelanotide (CUV1647)
    PhaseNot recorded
    Registry statusCompleted

  • Multicentre Phase III Erythropoietic Protoporphyria Study

    NCT04053270 · start 2007-05

    Registered record
    Registry ID
    NCT04053270
    Conditions
    Erythropoietic Protoporphyria
    Interventions
    Afamelanotide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-05
    Completion
    2009-12-09
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErythropoietic Protoporphyria
    InterventionAfamelanotide; Placebo
    PhasePhase 3
    Registry statusCompleted